What Is. Is the combination of two or more things to produce something that neither component could produce alone.

Similar documents
Consumer Health Care V5.0_2013

Innova&ve Medical Devices, Nutraceu&cals & Cosmeceu&cals. Company presenta&on Q1/2015

67 Years of Leadership in Pharmacy. A Journey of Continuous Improvement

Martindale Pharma is a UK pharmaceutical manufacturing company supplying niche products to over 50 countries worldwide.

Release of the 2017/18 Invitation to Tender

NATIVA GROUP. Inspired by Innovation and Technology

INTRODUCTORY TRAINING

Medical Developments International

Sub-components in Nicotine cessation products?

Philippine Strategy for the. Free Alternatives. under the National CFC Phase-out Plan (NCPP)

Partner with the Global Leader in Drug Delivery Systems

Therapeutic products for respiratory and autoimmune diseases. Annual General Meeting

Drug/Device Combination Products: Bioequivalence

300 3PORTUGUESE 65M GLOBAL WHO WE ARE WE OFFER PORTUGUESE

Boehringer Ingelheim and investment in R&D. Volker Barkmann

Injection Dosage Calculations

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

OPPORTUNITIES FOR OMEGA-3 PRODUCTS

Price List Effective 1June 2011.

UPLB-S , SUPPLY AND DELIVERY OF DRUGS AND MEDICINES TECHNICAL SPECIFICATION FOR THE PUBLIC BIDDING OF: OPENING OF BIDS:

innovative products. faster to market. reliably supplied.

Tamsulosin Hydrochloride 0.4 mg Capsule

Our mission is better health care outcomes.

Release of the 2013/14 Invitation to Tender

THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Buprenorphine pharmacology

Our mission is better health care outcomes.

Supply should only occur if requesting signature is on approved list held by the issuing pharmacy

Prescribing guidelines: Management of COPD in Primary Care

DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY

Our mission is better health care outcomes.

TRANSDERMAL INNOVATION

Understanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016

THE DOSING SPECIALIST

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

GUIDANCE DOCUMENT Non-prescription Oral Adult Nasal Decongestant Labelling Standard

PARENTERAL PREPARATIONS

innovative products. faster to market. reliably supplied.

LIST OF DRUGS DURING 2004

040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!

Value growth in Human Nutrition & Health

MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

No. Description Packing UOM

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA

GUIDELINE ON THE CATEGORISATION OF EXTENSION APPLICATIONS (EA) versus VARIATIONS APPLICATIONS (V) OCTOBER 2003

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

For personal use only

Stabilized Rice Bran Nutraceuticals & Functional Food The Road to Healthy Aging

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS

INFORMATION TOPIC: II-5 OR DEMONSTRATION: II-5. DOSAGE, MEASUREMENTS, AND DRUG FORMS (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Decentralised Procedure. Public Assessment Report. Buprenorphine SUN 2 mg/ 8 mg Sublingual tablets Buprenorphine hydrochloride DE/H/1577/ /DC

N a s d a q : I N S Y

Administration and Supply of Emergency Medicines

Mild Cognitive Impairment - Pipeline Review, H1 2017

BUILDING BUSINESS THROUGH SYNERGY

Location of HENGRUI. The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China

DATE OF PRE-BID CONFERENCE: DEADLINE OF SUBMISSION OF BIDS: OPENING OF BIDS:

Advance Notification of Amendments to the December 2018 Drug Tariff

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

Fundamentals of Pharmacology for Veterinary Technicians Chapter 1

The following list of recommended PDL changes were reviewed and approved by the MHS P&T Committee on December 14 th, 2016.

The Montreal Protocol and the Phase-out of CFC-based Metered Dose Inhalers. Paul Krajnik UNIDO, Montreal Protocol Branch

A world leader in allergy immunotherapy

Memree. Supports Cognitive Function and Stress Reduction. Memree. Nutrition

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack

DUAL CHAMBER SYSTEMS

Ensuring an Adequate Stockpile of Antivirals. Paul Brown F. Hoffmann La-Roche Basel, Switzerland

Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen

Approximate Cost for Patients

2019 Catalog Hospital and Ophthalmology Products and Services

Challenges in Developing Stable and Efficient Probiotic Formulations

Do not open the test booklet prior to being told to do so.

Company presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012

ANIMAL HEALTH DIVISION. Technologies & Services

MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

MEDICATION ASSISTED TREATMENT

TENDER RESULTS. Notification of Product Changes (NOPC) forms and Pharmacodes. 28 February 2014

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

Stockpiling of H5N1 vaccines

Orally Inhaled Corticosteroids to 2022

Welcome to Galenicum! APRIL, 2013

Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes

Caption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).

Industry Post-Regulation. E-Cigarette Summit Tim Phillips, ECigIntelligence. 17 th November

July Formulary Policy

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

Table updated 26 th February Salbutamol 26 th February Lofepramine hydrochloride 22 nd February Zoledronic acid 21 st February 2019

Breathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018

Opioid Conversion Guidelines

Controlled Delivery of Biologics NBC 22 June 2009

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

Singapore OTC Switching Regulation

KiOnutrime-CsG The proven weight management tool

TENDER RESULTS. Notification of Product Changes (NOPC) forms and Pharmacodes. 31 October 2014

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018

Transcription:

What Is Is the combination of two or more things to produce something that neither component could produce alone. 1

Our Skills Synergy Swiss Pharma has an experienced team with collective knowledge and familiarity with the global pharmaceutical network, which puts them in a position to offer comprehensive assistance and to build long-term partnerships. S y n e r g y S w i s s P h a r m a provides product development and subsequent regulatory services for all companies entering the regulated markets worldwide. Close association with the world pharmaceutical industry, and has wellentrenched global contacts to offer top quality API s, Formulation & technology transfer, sourced from the best global manufacturing facilities, at competitive pricing. 2

Why Choosing Us? We ensures deliverance of a complete development package matching the requirements of the high qualified generic industry. Our services include guidance in launching products in regulated markets like Europe, Japan, Korea, Asia, Middle East, Australia and New Zealand. We provide regulatory documentation, technical assistance, patent research assistance and other allied services. 3

Our Products Synergy Swiss Pharma has been expanding into different types of sectors with full development of finished dosage forms including regulatory files (European level) till the marketing. The company is specialized in respiratory, cardiovascular, psychiatry, gastroenterology, ophthalmology. Injectable of all forms, slow and fast release with new applications. Pharma Synergy Swiss has been expanding into different types of sectors, Active Pharmaceutical Ingredient, Intermediate Development, Medical Devices & Food Supplement with the development thanks to internal IP Department able to support Paragraph IV submission and to market the most interesting molecules for the coming years supported by a strong and well experienced R&D team. 4

Our Products: Respiratory Line Available Active ingredient Strength Presentation Budesonide 1mg/2ml - 0.5mg/2ml 0.25mg/2ml 200 mcg/actuation suspension for nebulisation MDI Fluticasone 50 mcg/actuation nasal spray Mometasone 50mcg/actuation nasal spray Salbutamol + Ipratropium 2.5mg + 0.5mg/2.5ml Solution for nebulization Salmeterol + Fluticasone 25mcg + 125mcg 25mcg + 250mcg 50mcg + 250mcg 50mcg + 500mcg MDI DPI Oct 2014 Products available only from and to countries where there is no valid patent protection and according to the applicable law 5

Our Products: Respiratory Line Under Development Active ingredient Strength Presentation Fluticasone 0.5mg/2ml 2mg/2ml suspension for nebulisation Tiotropium 18 mcg/capsule DPI Oct 2014 Products available only from and to countries where there is no valid patent protection and according to the applicable law 6

Our Products: Ophthalmic Line Available Active ingredient Strength Presentation Dorzolamide + Timolol 20mg+5 mg/ml single-dose vial and dropper Latanoprost 50 mcg/ml single-dose vial and dropper Latanoprost + Timolol 50mcg + 5mg/ml single-dose vial and dropper Tobramycin 3 mg/ml single-dose vial and dropper, also for auricular use Tobramycin + Dexamethasone 3mg+1mg/ml Travoprost 40 mcg/ml dropper single-dose vial and dropper Oct 2014 Products available only from and to countries where there is no valid patent protection and according to the applicable law 7

Our Products: Food Line More than 90 product formulations developed Our products are selling successfully in multiple markets All our products are manufactured at GMP-approved facilities in Germany and Italy All our products are developed to maximise the marketing possibilities to end-consumer, based on the type of registration, patents, and of course ingredients Scientific innovations: GoldenCaps a novel, patented dietary supplement helping to prevent the progressions of Dementia and Alzheimer Dermolipase a novel, patented treatment for Cellulites Hyamira cross-linked Hyaluronic Acid for beauty treatments Novel Mechanisms: Lenidor BB a pre- & probiotic, with a novel mechanism significantly prolonging shelf- life and ensuing highlevel activity of the pre-biotic Simethicone Bi-layer a novel mechanism allowing simethicone to be active in the stomach as well as the intestine. A Medical Device indicated to treat swelling of the stomach (aerophagia) and intestine (bloating) due to the accumulation of gas Regulatory approvals: CE-Medical devices: Menopause Patch Medical Device containing natural herbs for the treatment of menopause symptoms CE-Medical device registrations allow our distributors to communicate directly the product benefits to the end consumers 8

Our Products: Food Line Gliris GoldenCaps Lenidor BB Asterias Condramin Liponorma Nutrivita Force Pre & Post Sport Gel Hyamira Hyaluronic Acid inj Vijoint Hyaluronic Acid Dermolipase No Crave Uractiv complex Uromaxiflow Salusgate Flu Cough & Cold Spray & Tablets 9

Our Products: Food Line Menopause Patch Heat Anti-Pain Patch Natural Anti-Inflammatory & Rheumatic pain-relief Patch Flatbelly Re-flux tablet Re-flux liquid Psyllium Intestinal transit and colon propulsion 10

Our Products: Anesthetic Product Strenght Presentation Pack Therapeutic indications ORAMORPH (oral liquid morphine sulphate) MORPHINE HYDROCLHORIDE 10mg/5ml 30mg/5ml 2mg/ml 20mg/ml 10mg/ml 20mg/ml 50mg/5ml Udv s Plastic unit dose vials Syrup 100ml bottle (child proof and doser) Solution 20ml bottle drop (child proof and dropper) 10, 20 and 30 udv s Severe chronic pain Predictable Break through cancer pain Injectable forms 1 and 5 amps Acute pain PETHIDINE 100mg/2ml Injectable forms 1 glass amp Moderate to severe pain DEPALGOS (Oxycodone+Paracet amol) 5mg/325mg 10mg/325mg 20mg/325mg Tablets 14, 28, 56 tablets Moderate to severe chronic pain of degenerative origin under muscle-ostearticular illness. 11

Our Products: Anesthesia Product Strenght Presentation Pack Therapeutic indications ROPIVACAINE (hydrochloride vials & infusion) 2mg/ml 7,5mg/ml 10mg/ml Amp 10ml 20ml/Bags 100, 200ml Amp 10ml, 20ml Amp 10ml, 20ml Pack of 5 plastic amp Local and general anesthesia (motor block) Acute pain post-operative KETAMINE 50mg/ml Injectable amp 2ml Pack of 1 glass amp Anesthetic for diagnostic and surgical procedure L-BUPIVACAINE 2,5mg/ml 5mg/ml 7,5mg/ml 0,625mg/ml 1,25mg/ml Ampoules 10ml Amp 10ml Amp 10ml Bag 100ml,200ml Bag 100ml,200ml Pack of 10 Local and general anesthesia (motor block) Acute pain post-operative 12

Our Products: Addiction Product METHADONE (oral liquid solution) Stren ght 1mg/ml 5mg/ml 10mg/ml Presentation Pack Therapeutic indications 100ml, 500ml, 1000ml Bottle Treatment of heroin drug addiction dependence LEVO-METHADONE (oral liquid solution) BUPRENORPHINE 5mg/ml 100ml, 500ml bottle Treatment of heroin drug addiction dependence 2mg 8mg Sublingual tablets 7 or 14 tablets Treatment of heroin drug addiction dependence NALTREXONE 50mg Oral tables 14 or 28 tablets Treatment of alcohol dependence and detoxification NALOXONE 0,4mg/ml 0,04 mg/2ml Injectable amp 1 glass amps Used to counteract lifethreatening depression of the central nervous system and respiratory system. 13

Our Products: we are specializes also in Biotechnological Products Antibiotics Oncologics Neuroleptics Anticoagulants Blood Derivates Cardiovasculars Ophthalmics Narcotics Antiviral drugs 14

Our Partners 15

Contacts Via Luigi Lavizzari 4, 6850 Mendrisio / Switzerland tel:+41 (0) 91 980 91 62 fax: +41 (0) 91 930 70 71 Marketing Department: marketing@synergypharma.ch Commercial Department: commercial@synergypharma.ch www.synergypharma.ch 16